# Octreotide

## Sandostatin inj 0.1mg/1mL

##### 臨採

| TAH Drug Code      | [ISAN1](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ISAN1)                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | For patients with acromegaly who have not achieved adequate control with surgery, radiotherapy, or dopamine agonist therapy, this medication can help control symptoms and reduce plasma levels of growth hormone and somatomedin-C. It is also indicated for the relief of symptoms associated with gastroenteropancreatic endocrine tumors, prevention of postoperative complications following pancreatic surgery, treatment of bleeding from gastric and esophageal varices, and prevention of rebleeding.             |
| Dosing             | Acromegaly: Initially IM 0.05-0.1mg every 8-12 hour, could increased up to 1.5mg. Functional gastrointestinal pancreatic endocrine tumor: Initially IM 0.05mg 1-2 times per day, followed by 0.1-0.2mg three times per day. Complications after pancreatic surgery: IM 0.1mg three times per day for 7 days. Bleeding esophageal varices: diluted in normal saline and IV infusion 25mcg per hour for 5 days.                                                                                                              |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Known hypersensitivity to octreotide or one of the excipients (see Description) of Sandostatin                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Adverse Effects    | Anorexia, nausea, vomiting, crampy abdominal pain, abdominal bloating, flatulence, loose stools, steatorrhea, rarely progressive abdominal distension, severe epigastric pain, gallstones. Dermatologic: Injection site pain Endocrine metabolic: Hyperglycemia (1.5% to 16%), Hypoglycemia (1.5% to 3%), Hypothyroidism Gastrointestinal: Abdominal discomfort, Cholelithiasis (22% to 33% ), Constipation, Diarrhea, Flatulence, Nausea, Pancreatitis Hepatic: Disorder of biliary tract Neurologic: Dizziness, Headache |
| Pregnancy          | Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| More Info          | [UpToDate](https://www.uptodate.com/contents/octreotide-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

